Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654483 · ClinicalTrials.gov registry record · Phase 2
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
A Phase 2 study of Pruritus and Epidermolysis Bullosa, sponsored by Jean Yuh Tang.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT02654483 is a Phase 2 study of Pruritus and Epidermolysis Bullosa that has completed, run by Jean Yuh Tang. The registered enrollment target is 14 participants, below the 110-participant average among 12 other Pruritus trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02654483, a Phase 2 study of Pruritus and Epidermolysis Bullosa, has completed, sponsored by Jean Yuh Tang.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG VPD-737
Study Locations (1)
California
- Stanford - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2018-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02654483
The ClinicalTrials.gov registry entry for NCT02654483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 110-participant average among 12 other Pruritus trials with a reported enrollment target (87% lower). The listed sponsor is Jean Yuh Tang, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pruritus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02654483 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02654483 about?
NCT02654483 is a clinical study titled "Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients". Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
What is the current status of trial NCT02654483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2016-08-31. Estimated completion is 2018-07-27.
What conditions does trial NCT02654483 study?
This clinical trial studies the following conditions: Pruritus, Epidermolysis Bullosa.
What interventions are being tested in trial NCT02654483?
The interventions under investigation include: Placebo (OTHER), VPD-737 (DRUG).
Who is sponsoring clinical trial NCT02654483?
This trial is sponsored by Jean Yuh Tang, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02654483 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pruritus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
COMPLETED · Phase 2
-
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
COMPLETED · Phase 2
-
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
COMPLETED · Phase 2
-
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
COMPLETED · Phase 2
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
VR-PMR for Post-Burn Symptoms
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.